Assistance Publique des Hôpitaux de Paris SA

TFOX Regimen Shows Superior Efficacy Over FOLFOX in Advanced HER2-Negative Gastric Cancer

11 days ago

• French phase III PRODIGE 51-FFCD-GASTFOX trial demonstrates modified FLOT regimen (TFOX) significantly improves progression-free and overall survival compared to FOLFOX in advanced HER2-negative gastric cancer. • The TFOX regimen achieved a median overall survival of 15.1 months versus 12.7 months with FOLFOX, along with higher objective response rates (62.3% vs 53.4%) despite increased toxicity. • Researchers suggest TFOX represents a promising new first-line treatment option for patients eligible for docetaxel triplet chemotherapy, particularly those under 70 with good performance status.

AB Science Secures US Patent for Masitinib in Sickle Cell Disease Treatment Until 2040

a month ago

• AB Science has received a Notice of Allowance from the US Patent Office for masitinib in treating sickle cell disease, providing intellectual property protection until November 2040. • Masitinib uniquely targets mast cells in sickle cell disease treatment, showing promising preclinical results including complete prevention of vaso-occlusive crises and death in mouse models. • Clinical development is progressing through the SICKMAST program with €9.2 million funding, targeting both acute and chronic complications of sickle cell disease based on biomarker identification.

Dual Blood Pressure Medication Strategy Halves Arterial Events in vEDS Patients

3 months ago

• A Phase 3 ARCADE trial demonstrates that combining irbesartan with celiprolol reduces severe arterial events by 50% in vascular Ehlers-Danlos syndrome patients over two years. • The study showed significant reduction in both symptomatic and asymptomatic arterial lesions, with patients on irbesartan experiencing fewer events (13) compared to placebo (35). • Irbesartan, an affordable generic medication, demonstrated a favorable safety profile with only minor adjustments needed for blood pressure management in some patients.

Gastrointestinal Cancer Symposium 2025: Key Advances in Treatment Strategies

4 months ago

• Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer. • Encorafenib combined with cetuximab and chemotherapy shows significant improvement in overall response rate for BRAF V600E-mutated metastatic colorectal cancer. • TACE plus camrelizumab and rivoceranib extends progression-free survival in patients with unresectable hepatocellular carcinoma, offering a manageable safety profile.

J&J Seeks FDA Approval for TAR-200 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

4 months ago

• Johnson & Johnson has initiated a New Drug Application (NDA) submission to the FDA for TAR-200. • TAR-200 is intended for patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). • Phase 2b SunRISe-1 study data showed an 83.5% complete response rate with TAR-200 monotherapy. • The FDA is reviewing the application under the Real-Time Oncology Review (RTOR) program to expedite potential approval.

Opdivo Plus Yervoy Demonstrates Improved Outcomes in MSI-H/dMMR Metastatic Colorectal Cancer

5 months ago

• The combination of Opdivo and Yervoy significantly reduced the risk of disease progression or death by 38% compared to Opdivo alone in MSI-H/dMMR mCRC patients. • The CheckMate-8HW trial showed improved progression-free survival rates at 12, 24, and 36 months with the Opdivo/Yervoy combination versus Opdivo monotherapy. • The objective response rate was higher with Opdivo plus Yervoy (71%) compared to Opdivo alone (58%), indicating a greater proportion of patients experienced tumor shrinkage. • The safety profile of the Opdivo/Yervoy combination was consistent with previous findings, supporting its potential as a new standard of care.

Nivolumab Plus Ipilimumab Demonstrates Superior PFS in MSI-H/dMMR Metastatic Colorectal Cancer

6 months ago

• The combination of nivolumab and ipilimumab significantly improved progression-free survival (PFS) compared to chemotherapy in first-line treatment of MSI-H/dMMR mCRC. • CheckMate 8HW trial data showed a 72% PFS rate at 24 months with nivolumab/ipilimumab versus 14% with chemotherapy, establishing a new standard of care. • The dual immunotherapy also demonstrated a statistically significant improvement in PFS compared to nivolumab monotherapy across all lines of therapy. • While adverse events were more frequent with the combination, overall quality of life remained stable, supporting its use in MSI-H/dMMR mCRC.

Phaxiam Therapeutics Advances Phage Therapy with Phase 2 Trial for Staphylococcus aureus Vascular Graft Infections

7 months ago

• Phaxiam Therapeutics' PHAGOSCARPA, a phase 2 study, will assess anti-S. aureus phages for treating extra-cavitary vascular graft implant infections. • The trial, involving 80 patients across 27 French centers, aims to improve outcomes where mortality rates range from 10-25% within 30 days. • The primary endpoint is the therapeutic success rate at 3 months, evaluating clinical, functional, and radiological infection signs. • ANSM validation is expected in H1 2025, with Phaxiam supplying clinical doses and negotiating data access for potential future commercialization.

Nivolumab Plus Ipilimumab Demonstrates Superiority Over Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

a year ago

• The CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab significantly improved progression-free survival compared to chemotherapy in previously untreated patients with MSI-H/dMMR metastatic colorectal cancer. • The immunotherapy combination reduced the risk of disease progression or death by 79% compared to chemotherapy, with a hazard ratio of 0.21 (P < .0001). • At 24 months, the progression-free survival rate was 72% with nivolumab/ipilimumab versus 14% with chemotherapy, indicating a substantial and sustained benefit. • The safety profile of nivolumab plus ipilimumab was distinct from chemotherapy, with fewer grade 3/4 treatment-related adverse events.

Low-Dose Interleukin-2 Shows Promise in Slowing Motor Neurone Disease Progression in Landmark MIROCALS Trial

3 years ago

• The MIROCALS clinical trial demonstrated that low-dose interleukin-2 (IL2LD) is safe and reduced the risk of death by over 40% in approximately 80% of motor neurone disease patients with lower levels of a specific biomarker. • The groundbreaking study provides compelling evidence that modifying the immune system could be an effective strategy for altering MND/ALS progression, potentially adding to the disease-modifying effects of riluzole. • While not yet licensed for MND treatment, IL2LD increases regulatory T cells to reduce inflammation, and ILTOO Pharma has secured exclusive licensing rights to pursue regulatory approval for this novel therapeutic approach.